Salsola Kali Pollen

Dosage for Salsola Kali Pollen is highly individualized and must be determined by an allergist based on the patient's sensitivity level. There is no 'standard' dose, as the extract is non-standardized.

Build-up Phase (Escalation)

Treatment typically begins with a very dilute solution, such as 1:100,000 w/v or 1:10,000 w/v. Injections are usually given once or twice weekly. The volume is gradually increased (e.g., 0.05 mL, 0.10 mL, 0.20 mL, up to 0.50 mL) until the patient reaches the 'Maintenance Dose.' This phase usually lasts 3 to 6 months.

Maintenance Phase

Once the maximum tolerated dose is reached, the interval between injections is increased to every 2 to 4 weeks. A common maintenance dose range is 0.5 mL of a 1:100 w/v or 1:20 w/v concentration, depending on the manufacturer's specific product and the patient's tolerance. Maintenance therapy is generally continued for 3 to 5 years to ensure lasting immunity.

Salsola Kali Pollen extracts are generally considered safe for use in children, though immunotherapy is rarely started in children under the age of 5 due to the difficulty of monitoring for systemic reactions and the child's ability to communicate symptoms. The dosing logic for children is identical to that for adults: it is based on the individual's skin test reactivity and clinical tolerance rather than body weight.

Renal Impairment

No specific dose adjustments are required for patients with renal impairment, as the proteins are metabolized locally and systemically by proteases. However, the patient's overall health must be stable.

Hepatic Impairment

No dose adjustments are necessary for hepatic impairment. The liver does not play a primary role in the clearance of allergenic proteins.

Elderly Patients

Elderly patients may be at higher risk for complications if a systemic reaction occurs, particularly if they have underlying cardiovascular disease. Healthcare providers may choose a more conservative build-up schedule for patients over 65.

Salsola Kali Pollen must be administered by a trained healthcare professional in a clinical setting equipped to handle anaphylaxis.

• Route: Subcutaneous injection (SCIT) into the posterior aspect of the upper arm.
• Observation: Patients must remain in the clinic for at least 30 minutes following every injection to monitor for signs of a systemic reaction.
• Storage: Vials must be stored in a refrigerator at 2°C to 8°C (36°F to 46°F). They should never be frozen.
• Site Rotation: Injections should be rotated between arms to minimize local tissue irritation.

If a dose is missed during the build-up phase, the next dose may need to be reduced to ensure safety. If a dose is missed during the maintenance phase:

• Delay of 1-2 weeks: Usually, the same dose can be given.
• Delay of 3-4 weeks: The dose may be reduced by one or two increments.
• Delay of >4 weeks: The schedule may need to be restarted or significantly rolled back. Consult your allergist immediately if you miss an appointment.

An 'overdose' in the context of immunotherapy occurs when a dose is administered that exceeds the patient's current level of tolerance. This can lead to severe systemic reactions.

• Signs: Rapid onset of hives, swelling of the throat, wheezing, low blood pressure, or abdominal cramping.
• Emergency Measures: Administration of epinephrine (adrenaline) is the first-line treatment. Oxygen, intravenous fluids, and antihistamines may also be required.

> Important: Follow your healthcare provider's dosing instructions. Do not adjust your dose or attempt to self-administer these injections without medical guidance.

Most patients undergoing immunotherapy with Salsola Kali Pollen will experience some form of local reaction. These are generally not dangerous but can be uncomfortable.

• Local Swelling (Wheal): A raised, red area at the injection site that usually appears within minutes and resolves within a few hours. This is a normal response to the introduction of allergens.
• Pruritus (Itching): Itching at the site of injection is very common. It typically lasts for 1-2 hours.
• Erythema (Redness): Redness surrounding the injection site that may expand to the size of a half-dollar or larger.
• Tenderness: The arm may feel slightly sore or heavy for the remainder of the day.

• Large Local Reactions (LLR): Swelling that exceeds 5-10 cm in diameter. These may peak 6-12 hours after the injection and can last for 24-48 hours. While not systemic, they often require a dose adjustment for the next visit.
• Fatigue: Some patients report feeling unusually tired for several hours after their injection.
• Mild Nasal Congestion: A slight increase in hay fever symptoms shortly after treatment.

• Generalized Urticaria (Hives): Hives appearing on parts of the body distant from the injection site.
• Angioedema: Swelling of the deeper layers of the skin, often around the eyes or lips.
• Laryngeal Edema: Swelling of the throat, which is a medical emergency.
• Hypotension: A sudden drop in blood pressure, often associated with anaphylactic shock.

> Warning: Stop taking Salsola Kali Pollen and call your doctor immediately or seek emergency care if you experience any of these symptoms after an injection:

• Anaphylaxis: This is a life-threatening, whole-body allergic reaction. Symptoms include a rapid or weak pulse, skin rash, nausea, and vomiting.
• Dyspnea (Shortness of Breath): Any difficulty breathing, wheezing, or a feeling of chest tightness must be treated as a severe reaction.
• Syncope (Fainting): Feeling lightheaded or passing out can indicate a dangerous drop in blood pressure.
• Cyanosis: A bluish tint to the lips or fingernails, indicating a lack of oxygen.
• Persistent Cough: A dry, hacking cough that begins shortly after an injection can be a precursor to a severe asthma attack.

There are no known long-term 'toxic' effects of Salsola Kali Pollen extracts on organs like the liver, kidneys, or brain. The primary long-term risk is the development of increased sensitivity if the dosing is not managed correctly. However, for most patients, the long-term effect is a beneficial reduction in allergy symptoms and a decreased risk of developing new sensitizations or asthma.

Allergenic extracts, including Salsola Kali Pollen, carry a Class-Wide FDA Warning regarding the risk of severe systemic reactions.

Summary of Warning:

• This product can cause severe, life-threatening anaphylaxis.
• It must only be administered in a facility where emergency equipment and trained personnel are available to treat anaphylaxis.
• Patients with unstable or severe asthma are at a significantly higher risk for fatal reactions.
• Patients taking beta-blockers may be resistant to the effects of epinephrine, making a reaction harder to treat.
• Patients must be observed for at least 30 minutes after each injection.

Report any unusual symptoms or delayed reactions (occurring hours after you leave the clinic) to your healthcare provider immediately.

Salsola Kali Pollen is a potent biological agent. Its use is restricted to patients with a confirmed diagnosis of Russian Thistle allergy. It is not a general treatment for all types of hay fever. Patients must be informed that while immunotherapy can provide long-term relief, it carries an inherent risk of triggering the very allergic symptoms it is intended to treat.

No FDA black box warnings for Salsola Kali Pollen. However, it is subject to the standard 'Warning' section required for all allergenic extracts regarding anaphylaxis risk. The extract must be administered by physicians who are exceptionally familiar with the manifestations and treatment of systemic allergic reactions.

• Anaphylaxis Risk: Systemic reactions can occur at any time during treatment, even if the patient has tolerated previous injections perfectly. The risk is highest during the build-up phase and when starting a new vial of extract.
• Asthma Status: Patients must have their asthma under control before receiving an injection. If a patient is experiencing an asthma flare-up (e.g., peak flow is significantly lower than their personal best), the injection should be postponed. Uncontrolled asthma is the leading risk factor for fatal immunotherapy reactions.
• Injection Technique: Extreme care must be taken to avoid injecting the extract into a blood vessel (intravenous). Accidental IV injection can cause immediate, severe anaphylaxis because the allergen enters the bloodstream all at once.
• Infection/Illness: Injections should be delayed if the patient has a fever or a significant respiratory infection, as these conditions can lower the threshold for a systemic reaction.

• Pre-Injection Assessment: Every visit must include a check of the patient's current symptoms and a review of the reaction to the previous dose.
• Post-Injection Observation: A mandatory 30-minute wait time in the clinic is required for every patient, every time.
• Peak Flow Monitoring: For patients with asthma, a peak flow meter may be used to ensure lung function is stable before the injection is given.
• Vial Strength Verification: Nurses and doctors must double-check the concentration of the vial and the volume in the syringe to prevent dosing errors.

Generally, Salsola Kali Pollen does not cause drowsiness or impair cognitive function. However, if a patient experiences a systemic reaction or receives epinephrine, they should not drive or operate machinery until they have fully recovered and been cleared by a medical professional.

While there is no direct chemical interaction between alcohol and Salsola Kali Pollen, alcohol consumption can cause vasodilation (widening of blood vessels), which might theoretically increase the rate of allergen absorption or worsen the symptoms of an allergic reaction. It is advisable to avoid alcohol for several hours before and after an injection.

Immunotherapy is a long-term commitment. Stopping treatment prematurely (e.g., after only one year) often results in the return of symptoms. If treatment must be discontinued, there is no 'withdrawal' syndrome, but the patient will lose the immunological progress made. Tapering is not required for discontinuation, but if a patient wishes to restart after a long break, they must begin the build-up phase from the beginning.

> Important: Discuss all your medical conditions, especially heart or lung problems, with your healthcare provider before starting Salsola Kali Pollen.

There are no drugs that are strictly 'contraindicated' in the sense of a chemical reaction, but certain medications make the use of Salsola Kali Pollen unacceptably dangerous:

• Beta-Blockers (e.g., Propranolol, Atenolol): These medications are used for high blood pressure and heart conditions. They block the receptors that epinephrine (adrenaline) acts upon. If a patient on a beta-blocker has a severe allergic reaction to Salsola Kali Pollen, the standard life-saving treatment (epinephrine) may not work, leading to a potentially fatal outcome.

• ACE Inhibitors (e.g., Lisinopril, Enalapril): Some studies suggest that patients taking ACE inhibitors may be at an increased risk for more severe systemic reactions or may have a higher risk of 'rebound' symptoms during an allergic event.
• MAO Inhibitors (e.g., Phenelzine): These can interfere with the metabolism of medications used to treat anaphylaxis, potentially leading to a hypertensive crisis if emergency treatment is needed.

• Tricyclic Antidepressants (e.g., Amitriptyline): Similar to MAOIs, these can potentiate the effects of pressor amines (like epinephrine), which could complicate the management of a systemic reaction.
• Other Immunotherapy: If a patient is receiving multiple types of allergy shots (e.g., for dust mites or mold), the doses should be staggered or given in different arms to monitor which extract might be causing a local reaction.

• Cross-Reactive Foods: Some patients with Salsola Kali allergy may experience 'Oral Allergy Syndrome' when eating certain foods (like melons or bananas). While these don't interact with the injection directly, eating these foods around the time of an injection might increase the overall 'allergic load' and make a reaction more likely.
• High-Fat Meals: No known effect on the absorption of subcutaneous allergenic extracts.

• St. John's Wort: No known interaction.
• Immune-Stimulating Herbs (e.g., Echinacea): While not clinically proven to interact, patients should be cautious with supplements that claim to 'boost' the immune system, as immunotherapy is specifically designed to modulate the immune system in a very precise way.

• Skin Testing: If a patient is taking antihistamines (e.g., Cetirizine, Loratadine, Diphenhydramine), these will suppress the skin's reaction to Salsola Kali Pollen, leading to a false-negative result. Antihistamines must be stopped for 3 to 7 days before diagnostic testing.
• Specific IgE Blood Tests (RAST/ImmunoCAP): Salsola Kali Pollen treatment will eventually cause an increase in IgG4 levels and a potential decrease in IgE levels. This is a sign of treatment efficacy, not a 'lab interference.'

> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking, especially those for blood pressure or heart rhythm.

Salsola Kali Pollen must NEVER be used in the following circumstances:

• Recent Myocardial Infarction (Heart Attack): Patients who have had a heart attack within the last 3-6 months are at extreme risk if a systemic reaction occurs, as the heart may not tolerate the stress of anaphylaxis or the administration of epinephrine.
• Severe, Uncontrolled Asthma: If a patient's FEV1 (Forced Expiratory Volume) is consistently below 70% of their predicted value despite medication, the risk of a fatal respiratory reaction to an allergy shot is too high.
• Hypersensitivity to Excipients: Some extracts contain phenol as a preservative or glycerin. A known severe allergy to these components is a contraindication.

In these cases, the healthcare provider will perform a careful risk-benefit analysis:

• Autoimmune Diseases (e.g., Lupus, Rheumatoid Arthritis): There is a theoretical risk that stimulating the immune system with allergens could worsen an underlying autoimmune condition, though evidence for this is limited.
• Malignancy (Cancer): Patients undergoing active chemotherapy or with advanced cancer may have compromised immune systems that do not respond correctly to immunotherapy.
• Severe Eczema (Atopic Dermatitis): If the skin is severely inflamed, it may be difficult to interpret skin tests or monitor for local reactions.

Patients allergic to Salsola Kali (Russian Thistle) often show cross-sensitivity to other members of the Chenopodiaceae and Amaranthaceae families. This includes:

• Lamb's Quarter (*Chenopodium album*)
• Burning Bush (*Kochia scoparia*)
• Pigweed (*Amaranthus* species)

If a patient has had a severe reaction to any of these pollens, the starting dose for Salsola Kali Pollen should be extremely conservative.

> Important: Your healthcare provider will evaluate your complete medical history, including heart health and lung function, before prescribing Salsola Kali Pollen.

Salsola Kali Pollen is classified as Pregnancy Category C.

• Risk Summary: There are no adequate and well-controlled studies in pregnant women. However, the primary risk to the fetus is maternal anaphylaxis, which can cause fetal hypoxia (lack of oxygen).
• Clinical Practice: Allergists generally do not start new immunotherapy during pregnancy because the build-up phase carries the highest risk of reactions. However, if a woman is already on a stable maintenance dose and is tolerating it well, the treatment is usually continued, as stopping it could lead to an increase in asthma symptoms, which is also risky for the baby.

It is not known whether the allergenic components of Salsola Kali Pollen are excreted in human milk. However, since these are large proteins that are broken down in the mother's tissues, it is highly unlikely that they would reach the infant in any significant or active form. Breastfeeding is generally considered safe for mothers receiving immunotherapy.

• Approved Age: While there is no strict lower age limit, it is rarely used in children under 5 years old.
• Growth Effects: There is no evidence that allergenic extracts affect growth or development. In fact, some studies suggest that early immunotherapy can prevent the 'allergic march' (the progression from hay fever to asthma).
• Considerations: Children must be able to cooperate with the injection process and stay still for the 30-minute observation period.

Patients over 65 may receive Salsola Kali Pollen, but the physician must carefully screen for cardiovascular disease. The ability of an older patient to survive a systemic reaction is lower than that of a younger patient. Dose escalation may be done more slowly (e.g., every 2 weeks instead of weekly).

Renal function does not impact the safety or efficacy of Salsola Kali Pollen. No specific dose adjustments based on GFR (Glomerular Filtration Rate) are provided in the manufacturer's labeling. Dialysis does not clear the allergens from the body.

Liver disease does not affect the metabolism of allergenic proteins. No dose adjustments are required for patients with cirrhosis or other hepatic conditions, provided they are hemodynamically stable.

> Important: Special populations, particularly pregnant women and those with heart disease, require individualized medical assessment by an allergy specialist.

Salsola Kali Pollen contains several major allergens, most notably Sal k 1 (a pectin methylesterase). At the molecular level, immunotherapy works by:

1. 1Inducing T-cell Anergy: Making the T-cells that normally respond to the pollen 'unresponsive.'
2. 2T-reg Induction: Stimulating the production of regulatory T-cells that secrete IL-10.
3. 3B-cell Switching: Changing B-cell production from IgE (allergic) to IgG4 (protective).
4. 4Mast Cell Desensitization: Gradually increasing the threshold of allergen needed to trigger histamine release.

• Dose-Response: There is a clear dose-response relationship; higher maintenance doses generally lead to better long-term symptom control, but also carry a higher risk of side effects.
• Onset of Effect: Clinical improvement is rarely immediate. It typically takes 3 to 6 months (once the maintenance dose is approached) to see a reduction in symptoms.
• Duration of Effect: If a 3-5 year course is completed, the benefits can last for many years, or even a lifetime, after treatment is stopped.

| Parameter | Value |

|---|---|

| Bioavailability | N/A (Subcutaneous administration) |

| Protein Binding | N/A (Proteins interact with cell receptors) |

| Half-life | Variable (Proteins degraded within hours/days) |

| Tmax | 30-60 minutes (for systemic absorption) |

| Metabolism | Proteolytic degradation (Tissue proteases) |

| Excretion | Renal (as small peptides/amino acids) |

• Molecular Formula: Complex mixture of proteins (C, H, N, O, S).
• Molecular Weight: Ranges from 10 kDa to over 70 kDa for various allergen fractions.
• Solubility: Highly soluble in aqueous and glycerinated buffers.
• Description: A clear to slightly yellowish liquid extract derived from the defatted pollen of Salsola kali.

Salsola Kali Pollen is part of the Allergenic Extracts therapeutic class. It is specifically a 'Non-Standardized' extract, distinguishing it from 'Standardized' extracts like those for Grasses or Dust Mites which have federally mandated potency units.